TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06382532

Intervention type: DIAGNOSTIC_TEST
Intervention: Niacin skin reaction test
Description: Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Niacin skin reaction test
Description: Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Niacin skin reaction test
Description: Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.
Study: NCT05031585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roncoliv
Description: The medical device with nasal spray solution should be used 1 time a day, before bedtime, for 30 days.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The medical device with placebo should be used 1 time a day, before bedtime, for 30 days.
Study: NCT05814731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-BUCY2
Description: Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUCY2
Description: Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
Study: NCT00929461

Intervention type: DRUG
Group type: OTHER
Intervention: Lipovenoes® 10% and Omegaven®,
Description: All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.

Intervention type: DRUG
Group type: OTHER
Intervention: Lipovenoes® 10% and Omegaven®,
Description: All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
Study: NCT06581159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS135
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT05325827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided high fascia iliaca compartment block
Description: H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
Study: NCT04841837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding
Description: limit daily food intake to a period of 10 hours
Study: NCT05573958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: Rivaroxaban 2.5 mg oral tablet will be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel tablet
Description: Clopidogrel 75 mg once daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: Clopidogrel 75 mg once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin tablet
Description: Aspirin 81 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: Aspirin 81 mg tablet once daily
Study: NCT05164458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 308 injection
Description: IBI308 IV 200mg Q3W Day1
Study: NCT05105997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone/ Erector Spinae Plane Block
Description: Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
Study: NCT05888857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
Study: NCT04336033

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Renal Diet App
Description: Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Printed Nutrition Pamphlet
Description: After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions.
Study: NCT05624073

Intervention type: DEVICE
Intervention: Air-QTM Blocker
Description: The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes

Intervention type: DEVICE
Intervention: LarySealTM Pro
Description: The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in: sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr. Both devices accommodated standard conventional endotracheal tubes for intubation.
Study: NCT05164458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 389 Injection
Description: IBI 389 IV Q2\~Q3W Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 389 Injection
Description: IBI 389 IV Q2\~Q3W Day 1
Study: NCT04948697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1706
Description: 15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1706
Description: 15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
Study: NCT06008782

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HEARS-SLP device
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEARS-SLP device
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study: NCT05766176

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Antibody
Description: This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
Study: NCT05249569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib to be administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.
Study: NCT06008782

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HEARS-SLP program
Description: Tailored aural rehabilitation for participant and communication partner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEARS-SLP program
Description: Tailored aural rehabilitation for participant and communication partner
Study: NCT06361381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)
Description: Both concha will be swabbed with an alcohol wipe before applying a thin layer of conductive gel. An ear clip electrode will be placed in the concha of both ears.~A frequency of 25 Hz will be applied with a pulse duration of 200 µs. Every 5 minutes, the subject will be asked if the intensity can be increased, decreased or remain the same to maintain the same level of intensity. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)
Description: For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS will be applied on subject's forearm at a strong but comfortable intensity

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS will be applied on subject's forearm at a strong but comfortable intensity
Study: NCT06303791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Psychosocial intervention
Description: The psychosocial program with digital support has been developed by combining different theoretical perspectives on intervention in children with ASD without intellectual disabilities and children with ADHD. The contents of the program are based on three main approaches, each of which has separately demonstrated evidence in the treatment of these neurodevelopmental disorders: psychoeducation and stress management, cognitive behavioral techniques, and techniques in social and communication skills (Dahl et al., 2020; DuPaul et al., 2020; Tan-MacNeill et al., 2021).
Study: NCT04950777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education document
Description: The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
Study: NCT05644782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open wheat challenge
Description: Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo challenge
Description: Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
Study: NCT05514301

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection
Description: Both diagnostic interventions will be performed in all patients~1. High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~2. Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion.
Study: NCT06407466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taping
Description: Kinesiology taping; In order to facilitate the muscle, while the subject is standing and his body is flexed to ensure hip flexion, both I bands will be applied from the origin to the insertion, with 30% stretching from the medial and lateral, starting from the Ischial Tuberositas to the border of the Popliteal Fossa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The routine training program will continue without intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: Instrument-assisted soft tissue mobilization; The subject is in a prone position on a bed, with the lower extremity in a neutral position, and a hazelnut-sized amount of lubricant will be applied to the working surface, and will be applied to the skin on the back of the upper leg for 5 minutes, targeting the tissue structures. (Hamstring and deep fascia covering this muscle) Pressure and speed will be adjusted according to the subject's tolerance so as not to cause pain.
Study: NCT06045039

Intervention type: OTHER
Intervention: Stent-balloon-stent (SBS) technique
Description: Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1\~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
Study: NCT04686864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group for Caregivers
Description: Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children.
Study: NCT05210127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scarf osteotomy for Hallux Valgus deformity
Description: An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scarf osteotomy for Hallux Valgus deformity
Description: An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
Study: NCT06332118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice massage group
Description: Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
Study: NCT05334433

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia injection
Description: Local anesthesia administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia injection
Description: Local anesthesia administration
Study: NCT05699083

Intervention type: OTHER
Group type: OTHER
Intervention: Body Image/Self-Esteem Questionnaires
Description: Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.